Neither government agencies nor insurance companies will allow one company over dominate HVC market when a similar or quite close drug is available from another company. All around world we are moving to "social medicine".
I agree ABBV/ENTA should get some market share and I agree the market is pricing in very low expectations. I was just making a point that an insurance plan can't shut out GILD entirely regardless of pricing IF ABBV's regimen requires ribavirin now that we know GILD can do without it (unless the yet to be released data from ABBV without ribavirin are particularly strong, which is possible for 1b pts but doubtful for 1as based on ph 2 data)
Market Data 
Markets 
AI
